Literature DB >> 570116

Synthesis and antitumour activity of new daunorubicin and adriamycin analogues.

F Arcamone, L Bernardi, B Patelli, P Giardino, A Di Marco, A M Casazza, C Soranzo, G Pratesi.   

Abstract

A new synthetic procedure for the preparation of daunorubicin and adriamycin analogues bearing different substituents on ring D, has been developed. The new compounds display outstanding efficacy against experimental tumours of mice.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 570116     DOI： 10.1007/bf01981401

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  9 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Synthesis and antitumor activity of 4'-deoxydaunorubicin and 4'-deoxyadriamycin.

Authors:  F Arcamone; S Penco; S Redaelli; S Hanessian
Journal:  J Med Chem       Date:  1976-12       Impact factor: 7.446

3.  Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.

Authors:  F Arcamone; S Penco; A Vigevani; S Redaelli; G Franchi; A DiMarco; A M Casazza; T Dasdia; F Formelli; A Necco; C Soranzo
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

4.  Letter: Total synthesis of (+/-)-daunomycinone and (+/-)-carminomycinone.

Authors:  A S Kende; Y G Tsay; J E Mills
Journal:  J Am Chem Soc       Date:  1976-03-31       Impact factor: 15.419

5.  Letter: Regiospecif total synthesis of (plus or minus)-9-deoxy daunomycinone.

Authors:  A S Kende; J Belletire; T J Bentley; E Hume; J Airey
Journal:  J Am Chem Soc       Date:  1975-07-23       Impact factor: 15.419

6.  New antitumor anthracyclines.

Authors:  F Arcamone
Journal:  Lloydia       Date:  1977 Jan-Feb

7.  Synthesis and biological evaluation of some 14-O-acyl derivatives of adriamycin.

Authors:  F Arcamone; G Franceschi; A Minghetti; S Penco; S Redaelli
Journal:  J Med Chem       Date:  1974-03       Impact factor: 7.446

8.  Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers.

Authors:  F Arcamone; L Bernardi; P Giardino; B Patelli; A Marco; A M Casazza; G Pratesi; P Reggiani
Journal:  Cancer Treat Rep       Date:  1976-07

9.  Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4' -epiadriamycin.

Authors:  A Di Marco; A M Casazza; F Giuliani; G Pratesi; F Arcamone; L Bernardi; G Franchi; P Giardino; B Patelli; S Penco
Journal:  Cancer Treat Rep       Date:  1978-03
  9 in total
  5 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.

Authors:  C B Vaughn; S E Salmon; T R Fleming
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

3.  Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer.

Authors:  G Falkson; D A Vorobiof
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

4.  A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography.

Authors:  Y M Peng; D S Alberts; S E Salmon; T P Davis
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

5.  First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.

Authors:  Yiwei Jiang; Wenjin Yin; Liheng Zhou; Tingting Yan; Qiong Zhou; Yueyao Du; Zhenzhou Shen; Zhimin Shao; Jinsong Lu
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.